Morgan Stanley Downgrades Teva Pharma (TEVA) to Equalweight

Morgan Stanley downgraded Teva Pharma (NYSE: TEVA) from Overweight to Equalweight with a price target of $42.00 (from $63.00).

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $37.60 yesterday.

You May Also Be Interested In

• Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
• VTEX (VTEX) PT Lowered to $5.10 at Jefferies
• Yihai International Holding Ltd. (1579:HK) (YNNHF) PT Raised to HK$21.50 at Goldman Sachs